Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts.
Candidemia
Intra-abdominal candidiasis
Risk factors
Septic shock
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
26 03 2020
26 03 2020
Historique:
received:
19
10
2019
accepted:
17
02
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
3
4
2020
Statut:
epublish
Résumé
Almost one third of the patients with candidemia develop septic shock. The understanding why some patients do and others do not develop septic shock is very limited. The objective of this study was to identify variables associated with septic shock development in a large population of patients with candidemia. A post hoc analysis was performed on two prospective, multicenter cohort of patients with candidemia from 12 hospitals in Spain and Italy. All episodes occurring from September 2016 to February 2018 were analyzed to assess variables associated with septic shock development defined according to The Third International Consensus Definition for Sepsis and Septic Shock (Sepsis-3). Of 317 candidemic patients, 99 (31.2%) presented septic shock attributable to candidemia. Multivariate logistic regression analysis identifies the following factors associated with septic shock development: age > 50 years (OR 2.57, 95% CI 1.03-6.41, p = 0.04), abdominal source of the infection (OR 2.18, 95% CI 1.04-4.55, p = 0.04), and admission to a general ward at the time of candidemia onset (OR 0.21, 95% CI, 0.12-0.44, p = 0.001). Septic shock development was independently associated with a greater risk of 30-day mortality (OR 2.14, 95% CI 1.08-4.24, p = 0.02). Age and abdominal source of the infection are the most important factors significantly associated with the development of septic shock in patients with candidemia. Our findings suggest that host factors and source of the infection may be more important for development of septic shock than intrinsic virulence factors of organisms.
Sections du résumé
BACKGROUND
Almost one third of the patients with candidemia develop septic shock. The understanding why some patients do and others do not develop septic shock is very limited. The objective of this study was to identify variables associated with septic shock development in a large population of patients with candidemia.
METHODS
A post hoc analysis was performed on two prospective, multicenter cohort of patients with candidemia from 12 hospitals in Spain and Italy. All episodes occurring from September 2016 to February 2018 were analyzed to assess variables associated with septic shock development defined according to The Third International Consensus Definition for Sepsis and Septic Shock (Sepsis-3).
RESULTS
Of 317 candidemic patients, 99 (31.2%) presented septic shock attributable to candidemia. Multivariate logistic regression analysis identifies the following factors associated with septic shock development: age > 50 years (OR 2.57, 95% CI 1.03-6.41, p = 0.04), abdominal source of the infection (OR 2.18, 95% CI 1.04-4.55, p = 0.04), and admission to a general ward at the time of candidemia onset (OR 0.21, 95% CI, 0.12-0.44, p = 0.001). Septic shock development was independently associated with a greater risk of 30-day mortality (OR 2.14, 95% CI 1.08-4.24, p = 0.02).
CONCLUSIONS
Age and abdominal source of the infection are the most important factors significantly associated with the development of septic shock in patients with candidemia. Our findings suggest that host factors and source of the infection may be more important for development of septic shock than intrinsic virulence factors of organisms.
Identifiants
pubmed: 32216822
doi: 10.1186/s13054-020-2793-y
pii: 10.1186/s13054-020-2793-y
pmc: PMC7099832
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Subventions
Organisme : Instituto de Salud Carlos III
ID : PI15/00744
Pays : International
Références
Rev Iberoam Micol. 2018 Jul - Sep;35(3):159-161
pubmed: 30343837
Am J Ther. 2009 Nov-Dec;16(6):508-11
pubmed: 19531934
Intensive Care Med. 2014 Jun;40(6):839-45
pubmed: 24807083
PLoS One. 2017 Jul 27;12(7):e0181439
pubmed: 28750040
Hosp Pract (1995). 2018 Dec;46(5):258-265
pubmed: 30170000
Intensive Care Med. 2015 Aug;41(8):1424-32
pubmed: 26134359
Liver Int. 2019 Jul;39(7):1263-1270
pubmed: 30790420
Am J Infect Control. 2018 Nov;46(11):1299-1300
pubmed: 29884575
Intensive Care Med. 2015 Jun;41(6):975-84
pubmed: 25862039
Shock. 2018 Jan;49(1):62-70
pubmed: 28498297
Clin Microbiol Infect. 2014 Apr;20(4):O245-54
pubmed: 24125548
Intensive Care Med. 2015 Sep;41(9):1601-10
pubmed: 26077063
PLoS One. 2017 Oct 18;12(10):e0185339
pubmed: 29045423
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Microbiol Infect. 2013 Jun;19(6):E281-4
pubmed: 23414070
Infect Dis (Lond). 2015 Aug;47(8):584-7
pubmed: 25811137
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223375
Am J Emerg Med. 2017 Nov;35(11):1730-1733
pubmed: 28712645
Intern Emerg Med. 2018 Mar;13(2):199-204
pubmed: 29322386
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur J Intern Med. 2016 Oct;34:39-44
pubmed: 27553696
J Clin Med Res. 2011 Apr 4;3(2):65-71
pubmed: 21811532
Am J Respir Crit Care Med. 2013 Nov 1;188(9):1100-9
pubmed: 23782027
West J Emerg Med. 2018 Sep;19(5):774-781
pubmed: 30202487
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Intensive Care Med. 2013 Dec;39(12):2092-106
pubmed: 24105327
Shock. 2020 Feb;53(2):189-198
pubmed: 30829903
Clin Infect Dis. 2012 Jun;54(12):1739-46
pubmed: 22423135
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
Infection. 2016 Dec;44(6):747-755
pubmed: 27401690
Scand J Trauma Resusc Emerg Med. 2017 Jun 9;25(1):56
pubmed: 28599661
Clin Infect Dis. 2017 May 15;64(10):1374-1379
pubmed: 28329281
Am J Med. 2016 Dec;129(12):1330.e1-1330.e6
pubmed: 27452680
J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv6-iv12
pubmed: 29608751
Crit Care. 2017 Oct 31;21(1):268
pubmed: 29089025
Crit Care Med. 2017 Nov;45(11):1805-1812
pubmed: 28737573
Crit Care. 2019 Jun 14;23(1):219
pubmed: 31200780
Med Mycol. 2019 Aug 1;57(6):659-667
pubmed: 30418567
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):607-614
pubmed: 30680572
Intensive Care Med. 2017 Apr;43(4):509-518
pubmed: 28271321